Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. - Wikidata - wikimedia - TriplyDB

Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas.

Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas.

http://www.wikidata.org/entity/Q40491223

about

Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders Epstein-Barr virus lytic infection induces retinoic acid-responsive genes through induction of a retinol-metabolizing enzyme, DHRS9 Reversible iatrogenic, MTX-associated EBV-driven lymphoproliferation with histopathological features of a lymphomatoid granulomatosis in a patient with rheumatoid arthritis Clinical Features and Outcomes of Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated Inflammation: Prospective Characterization of KSHV Inflammatory Cytokine Syndrome (KICS).Newly emerging therapies targeting viral-related lymphomas.Viral response to chemotherapy in endemic burkitt lymphoma Noise cancellation: viral fine tuning of the cellular environment for its own genome replication.Either ZEB1 or ZEB2/SIP1 can play a central role in regulating the Epstein-Barr virus latent-lytic switch in a cell-type-specific manner.Interferon regulatory factor 7 is negatively regulated by the Epstein-Barr virus immediate-early gene, BZLF-1 Cellular microRNAs 200b and 429 regulate the Epstein-Barr virus switch between latency and lytic replication.Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model.Detection of EBV genomes in plasmablasts/plasma cells and non-B cells in the blood of most patients with EBV lymphoproliferative disorders by using Immuno-FISH.Sulfated small molecules targeting eBV in Burkitt lymphoma: from in silico screening to the evidence of in vitro effect on viral episomal DNA.Epstein-Barr virus-associated lymphomas.Theodore E. Woodward Award: development of novel, EBV-targeted therapies for EBV-positive tumors Bortezomib induction of C/EBPβ mediates Epstein-Barr virus lytic activation in Burkitt lymphoma.Effects of a biologic agent in a patient with rheumatoid arthritis after treatment for methotrexate-associated B-cell lymphoma: a case report.Primary central nervous system lymphoma in a rheumatoid arthritis patient treated with methotrexate: a case report.The role of PI3K/Akt in human herpesvirus infection: From the bench to the bedside A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory.Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia Acute Hepatitis E Virus infection with coincident reactivation of Epstein-Barr virus infection in an immunosuppressed patient with rheumatoid arthritis: a case report.LMP1-Induced Sumoylation Influences the Maintenance of Epstein-Barr Virus Latency through KAP1 ATM facilitates mouse gammaherpesvirus reactivation from myeloid cells during chronic infection.X-box-binding protein 1 activates lytic Epstein-Barr virus gene expression in combination with protein kinase D.Cross talk between EBV and telomerase: the role of TERT and NOTCH2 in the switch of latent/lytic cycle of the virus Epstein-Barr Virus (EBV) Tegument Protein BGLF2 Promotes EBV Reactivation through Activation of the p38 Mitogen-Activated Protein Kinase.Evidence that amphotericin B mediates reactivation of latent Epstein-Barr virus in Hodgkin's lymphoma allowing cytotoxicity by acyclovir Epstein-barr virus infected gastric adenocarcinoma expresses latent and lytic viral transcripts and has a distinct human gene expression profile Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases.Diagnostic and therapeutic challenges of EBV-positive mucocutaneous ulcer: a case report and systematic review of the literature.Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.Oropharyngeal shedding of Epstein-Barr virus in the absence of circulating B cells.EBV Zta protein induces the expression of interleukin-13, promoting the proliferation of EBV-infected B cells and lymphoblastoid cell lines.Development of drugs for Epstein-Barr virus using high-throughput in silico virtual screening Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder.Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation.Epstein-Barr virus genetics: talking about the BAC generation.Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma.

P2860

Q26776151-70322189-DB49-44F2-BCA4-1D6C5BD1F8F9 Q28284628-3894E4B1-9424-43CE-BC5A-727F0CE8A8B7 Q28287778-7E156C60-28D2-4D48-9BBF-B09B834E16F2 Q33428328-2F727FDB-77E7-4ABA-BF69-D7C8D12C1F6E Q33699201-86BABBB7-E167-4526-B6BA-B7DF83443214 Q33767066-8DA0CAFE-8173-4076-823D-3041CDA463B9 Q33780955-38E4CAC9-6DCE-4514-AC3C-4303F2E31479 Q33877497-E93E18D9-8ADE-41B1-AA7F-5144E25EE20F Q33908810-5E138648-0B3C-4AD7-A062-8AA467B5FEA2 Q34120915-00473E9A-5504-4395-9726-09DCED48B1B8 Q34123985-616B2615-4780-4BEB-96FD-E5495D8D4C3D Q34374063-AE9DCF4B-7170-4A83-B31E-EEC347BBBDD5 Q34563797-F8472B87-0D51-4053-8190-BBD9F332CE6C Q34651670-7905B42B-838F-4943-881F-BBA8465ED31A Q34767204-52CEE9FD-0AE5-4E33-B377-63292A6BF842 Q35067397-19909895-8419-4F82-BCAF-B47AAF646C71 Q35144770-B9431D9F-7769-4D37-B78F-0B0A147BD956 Q35204309-4328B3DA-B981-42CE-98DD-1FB0A8F7A6CC Q35582498-548E8479-61B8-4A89-B037-184DCB9E2175 Q35586049-1DF70D6C-8B89-4351-8ED2-DA0E2BAC3D61 Q35669193-390C420B-9896-4B52-BF7C-45F571526826 Q35751004-F88F3F08-87AE-47C2-887C-7271F3964A7E Q35825073-DF75C6CD-749F-424A-85A5-F8D1CFDEC484 Q35861199-917E5324-A8CF-461D-8706-AD74666D0EE3 Q35893600-3EB2431B-477F-4363-96D9-FE797C96C5ED Q35914523-4A887C3B-F1B6-49FD-9CCA-E049F820249F Q36346985-494FBFBA-B02F-48EB-9960-10B6DB55BC6B Q36434206-3394AD11-A5E7-45F1-8C3D-2FF5C5843D2A Q36461784-2BE16D57-F6FA-4A89-BE27-41853A891C35 Q36687528-26D01E51-D3F0-4ABE-A6E9-E610FE2094C2 Q36747670-C37FC3CE-0148-48B7-9571-9CBC2282E39A Q36846805-E8DBCE4C-9057-45B4-85BD-EB24BBEE0A8E Q37146126-3E1D66F3-CC3F-4BE4-90A4-BC020E8EA442 Q37185783-6C8F0A16-AAE1-44D5-9C05-213DD7BECC4B Q37262460-B6AFBEDE-7E06-40B3-AE05-4F9AD07DF0C7 Q37278489-FB0CFBDB-B855-484C-80A7-38EA5FBC185D Q37726624-DCED9E5E-BE5C-4E6A-AC68-C110946F8184 Q37793222-F410E884-ECA3-4260-A3E0-887FC244A84E Q37856451-5618804F-058C-4F9E-A9BB-7C18E9F74564 Q38068839-08785044-68A3-4175-B244-EC1DF3CAE83D

P2860

Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas.

http://www.wikidata.org/entity/Q40491223

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh

2004年學術文章

@zh-hant

name

Reactivation of latent Epstein ...... otrexate-associated lymphomas.

@en

type

label

Reactivation of latent Epstein ...... otrexate-associated lymphomas.

@en

prefLabel

Reactivation of latent Epstein ...... otrexate-associated lymphomas.

@en

P1433

Q40491223-CA741105-6EC8-460C-B8B3-DEF7E83F7720

P1476

Q40491223-5EC83842-315C-4038-93EA-3D6F2AA787CE

P2093

Q40491223-189C0C23-A7AA-4E8C-AF95-90D0A14B59FC

Q40491223-399AF76F-C5A3-470B-843F-2422EC0051C2

Q40491223-44DF8556-8915-4093-9494-EB568EA3F913

Q40491223-849FBEF8-DF43-47A2-9273-97103B31D26D

Q40491223-97557C5E-0F86-4E04-967D-C045D8A65EC0

Q40491223-9E21923B-8B91-47B8-B998-A9F650263459

Q40491223-A2B5FA60-6CC2-4678-B192-09356E177A99

Q40491223-C9E616E1-CE77-4034-A6D8-E43E19D97233

P2860

Q40491223-02A2AFD6-AB42-4DB0-A877-4B90A518E311

Q40491223-0FFCA0B1-689E-45E1-9E3A-19E930612B6C

Q40491223-11F797DF-76E7-47B4-B030-1A8E944FF76F

Q40491223-1967AD9B-43B9-4391-A778-53464D3F492C

Q40491223-20DF1DC3-DDF4-4487-883D-D63772A5011B

Q40491223-21771CF8-79B4-49C9-B84E-76DBA9067A37

Q40491223-30BCE663-0058-463D-AECF-08581FB40724

Q40491223-33585F18-071E-4CB3-AB9B-3999D1DF04F7

Q40491223-37703B38-22F1-4B66-9855-87E70E94A17F

Q40491223-49D921A8-2F54-4910-84EF-FA8277872A37

P304

Q40491223-A7F49710-6D64-44F4-9A44-2D6C884B2C80

P31

Q40491223-F900B5F8-F60B-4FAA-BAD2-7DC20788F8E2

P356

Q40491223-F7185ED5-689C-46F3-99C0-E0BACD4F2DC5

P407

Q40491223-90B00C26-A6E7-4403-9103-264FC9FB2F0E

P433

Q40491223-0D45BEA8-44E0-4DD6-BF95-395AA725E733

P478

Q40491223-618E6DA6-2F95-44ED-8AAB-C2B37B218964

P50

Q40491223-5BEC4A5F-6179-4509-96CF-AA0A90A8335E

P577

Q40491223-19938D6B-BA11-4349-AFB7-AFFC57575889

P5875

Q40491223-4A26EE3A-A5E2-4BB1-A40F-F3E6DBA3A4ED

P698

Q40491223-6B19FABE-9628-4A70-80B2-BC6B9EAAFDC7

P921

Q40491223-F39722E8-0A58-433C-8BCC-6BDAD53CDC95

P356

P1433

Journal of the National Cancer Institute

P1476

Reactivation of latent Epstein ...... otrexate-associated lymphomas.

@en

P2093

Jeffrey I Cohen

http://www.w3.org/2001/XMLSchema#string

Li Li

http://www.w3.org/2001/XMLSchema#string

Michael Sneller

http://www.w3.org/2001/XMLSchema#string

Nancy Raab-Traub

http://www.w3.org/2001/XMLSchema#string

Raphael Goldbach-Mansky

http://www.w3.org/2001/XMLSchema#string

Shannon C Kenney

http://www.w3.org/2001/XMLSchema#string

Steven Fischer

http://www.w3.org/2001/XMLSchema#string

Wen-hai Feng

http://www.w3.org/2001/XMLSchema#string

P2860

Regulation of the MEF2 family of transcription factors by p38

Signal Transduction and Transcription Factor Modification during Reactivation of Epstein-Barr Virus from Latency

Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells

Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca(2+)-ATPase gene transcription

Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT.

Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases

Epstein-Barr virus immediate-early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation.

Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues

Epstein-Barr virus infection.

DNA sequence and expression of the B95-8 Epstein-Barr virus genome.

P304

1691-1702

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJH313

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

96

http://www.w3.org/2001/XMLSchema#string

P50

Henri-Jacques Delecluse

P577

2004-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8180320

http://www.w3.org/2001/XMLSchema#string

P698

15547182

http://www.w3.org/2001/XMLSchema#string

P921

Epstein–Barr virus